Alnylam Pharmaceuticals ALNY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.29B+15.4% | $3.71B+15.7% | $3.21B+30.4% | $2.46B+4.8% | $2.35B+4.4% | ||
| $814.5M+20.3% | $677.17M+32.2% | $512.09M+29.0% | $396.84M+23.2% | $322.08M+5.1% | ||
| $3.47B+14.3% | $3.04B+12.6% | $2.7B+30.6% | $2.07B+1.9% | $2.03B+4.3% | ||
| 81%-0.8pp | 81.8%-2.3pp | 84%+0.2pp | 83.9%-2.4pp | 86.3%-0.1pp | ||
| $1.42B+7.6% | $1.32B+5.8% | $1.25B+7.6% | $1.16B+2.6% | $1.13B+0.4% | ||
| $1.29B+6.8% | $1.21B+2.5% | $1.18B+9.4% | $1.08B+7.5% | $1B+3.0% | ||
| $3.53B+10.0% | $3.21B+9.1% | $2.95B+11.5% | $2.64B+7.3% | $2.46B+1.6% | ||
| $752.14M+50.0% | $501.58M+89.5% | $264.7M+247% | -$180.19M-56.2% | -$115.37M+34.8% | ||
| 17.5%+4.0pp | 13.5%+5.3pp | 8.2%+15.6pp | -7.3%-2.4pp | -4.9%+3.0pp | ||
| $219.33M+5.3% | $208.35M+14.5% | $181.92M+5.8% | $171.9M+4.2% | $164.91M+16.3% | ||
| $109.4M-1.9% | $111.47M-3.8% | $115.86M-2.9% | $119.32M-1.4% | $121.02M-0.8% | ||
| -$240.61M-12.4% | -$214.07M+16.8% | -$257.42M-60.7% | -$160.16M+20.2% | -$200.78M-0.1% | ||
| $511.53M+77.9% | $287.5M+3,847% | $7.29M+102% | -$340.35M-7.7% | -$316.16M+16.2% | ||
| —— | —— | -$75.51M-24.8% | -$60.49M+29.4% | -$85.68M+13.6% | ||
| $502.34M+80.6% | $278.1M+236% | $82.79M+130% | -$279.86M-21.4% | -$230.47M+17.1% | ||
| 11.7%+4.2pp | 7.5%+4.9pp | 2.6%+13.9pp | -11.4%-1.6pp | -9.8%+2.6pp | ||
| $3.66+82.1% | $2.01+272% | $0.54+125% | -$2.17-21.2% | -$1.79+17.5% | ||
| $3.79+80.5% | $2.10+244% | $0.61+128% | -$2.17-21.2% | -$1.79+17.5% | ||
| 540.9M+1.6% | 532.3M+1.3% | 525.3M+1.7% | 516.5M+0.8% | 512.7M+0.7% | ||
| 526M+0.6% | 522.8M+0.6% | 519.4M+0.6% | 516.5M+0.8% | 512.7M+0.7% | ||
| $7.45M+58.3% | $4.71M-3.4% | $4.87M-17.1% | $5.88M-7.5% | $6.35M-62.3% | ||
| $16.44M+50.8% | $10.9M-2.5% | $11.19M— | —— | —— | ||
| $514.96M+76.0% | $292.52M+241% | $85.84M+131% | -$275.18M-14.2% | -$241M+16.7% | ||
| -$2.53M-15.0% | -$2.2M+97.3% | -$82.42M+6.5% | -$88.18M+9.6% | -$97.58M+8.6% | ||
| $54.81M-1.5% | $55.66M-1.2% | $56.32M-0.3% | $56.5M-1.8% | $57.56M+1.6% | ||
| —— | —— | —— | —— | $15.34M+6.8% | ||
| —— | —— | $603.72M+151% | $240.95M+155% | $94.39M+9.1% | ||
| -$27.25M+48.5% | -$52.94M+19.5% | -$65.75M-16.7% | -$56.34M+75.9% | -$234.2M+0.5% | ||
| —— | —— | -$23.18M+3.9% | -$24.13M-22.0% | -$19.78M-45.6% | ||
| $98.06M-21.2% | $124.5M+341% | $28.23M+79.1% | $15.77M+134% | -$45.92M-1,322% | ||
| $213.98M-2.2% | $218.71M+85.8% | $117.72M+7.0% | $109.97M+4.2% | $105.56M+56.2% | ||
| —— | —— | -$319.51M-238% | $231.59M-25.6% | $311.33M+5.8% | ||
| $334.18M-29.4% | $473.5M+12.6% | $420.59M+480% | -$110.77M— | —— | ||
| $714.9M+36.4% | $524.08M+97.1% | $265.86M+1,811% | -$15.54M+67.0% | -$47.11M-467% | ||
| -$2.86M-258% | $1.82M+161% | -$2.97M-160% | $4.98M+8.4% | $4.59M+114,950% | ||
| -$8.28M-259% | $5.2M+103% | -$152.21M-41.5% | -$107.58M+31.4% | -$156.89M+13.1% | ||
| —— | —— | —— | -$58.56M-13.0% | -$51.83M-32.9% | ||
| $1.17B-10.7% | $1.31B-16.1% | $1.56B-12.5% | $1.78B+10.0% | $1.62B-1.1% | ||
| $71.56M+21.9% | $58.7M+31.9% | $44.5M+21.8% | $36.55M+20.7% | $30.27M-11.7% | ||
| $213.82M-14.5% | $250.03M+2.2% | $244.61M-11.0% | $274.9M-15.8% | $326.46M+7.8% | ||
| $4.29B+15.4% | $3.71B+15.7% | $3.21B+30.4% | $2.46B+4.8% | $2.35B+4.4% | ||
| $361.68M+3.9% | $348.24M-5.4% | $368.25M+20.4% | $305.84M+7.9% | $283.45M+4.2% | ||
| $806.94M+44.8% | $557.24M+73.6% | $321.02M+360% | -$123.69M-114% | -$57.82M+51.9% | ||
| 18.8%+3.8pp | 15%+5.0pp | 10%+15.0pp | -5%-2.6pp | -2.5%+2.9pp | ||
| $752.14M+50.0% | $501.58M+89.5% | $264.7M+247% | -$180.19M-56.2% | -$115.37M+34.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
- Is Alnylam Pharmaceuticals profitable?
- Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
- What are Alnylam Pharmaceuticals's profit margins?
- Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
- What is Alnylam Pharmaceuticals's earnings per share?
- Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
- Where does Alnylam Pharmaceuticals's income statement data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
